Abogen Showcases Promising Preliminary Results for ABO2203 in B-NHL at AACR 2026#USA#San_Diego#TCE#Abogen#ABO2203
Abogen Showcases Promising Preliminary Results for ABO2203 in B-NHL at AACR 2026
At AACR 2026, Abogen revealed preliminary findings from the first human trials of ABO2203, suggesting a strong safety profile and encouraging response rates in treating B-NHL.
third-news.com
April 20, 2026 at 2:12 PM
Abogen Showcases Promising Preliminary Results for ABO2203 in B-NHL at AACR 2026#USA#San_Diego#TCE#Abogen#ABO2203
Abogen Unveils Promising Findings from mRNA Therapy in 2026 AACR Conference#USA#San_Diego#mRNA_Therapy#Abogen#ABO2203
Abogen Unveils Promising Findings from mRNA Therapy in 2026 AACR Conference
Abogen, a pioneering biotech firm, presented promising preliminary results for their new mRNA therapy ABO2203 at the AACR 2026 conference in San Diego, showcasing safety and efficacy in treating relapsed B-cell lymphoma.
third-news.com
April 20, 2026 at 2:08 PM
Abogen Unveils Promising Findings from mRNA Therapy in 2026 AACR Conference#USA#San_Diego#mRNA_Therapy#Abogen#ABO2203